Benign Prostate Tissue (Negative for Malignancy): Understanding Your Pathology Report

Section Editor: Trevor Flood MD FRCPC
October 27, 2026

Benign prostate tissue is the result given when a pathologist examines tissue from the prostate gland and finds no cancer. Benign means the cells and tissue examined are not cancerous. Your report may use a different phrase for the same result, such as negative for malignancy, benign prostatic tissue, or no evidence of carcinoma. A benign result is the most common result of a prostate biopsy, and it means no cancer was seen in the tissue.

This article explains what a benign prostate biopsy result means and how the pathologist reaches it. It also explains the harmless changes that are often listed in the report, why a benign biopsy cannot completely rule out cancer, and the follow-up your care team may discuss.

Why is a prostate biopsy done?

A prostate biopsy is usually done to look for prostate cancer. The most common reasons are a raised prostate-specific antigen (PSA) blood test, an abnormal rectal examination, or an area that looks suspicious on an MRI. During the biopsy, a thin needle removes several narrow cores of tissue from different parts of the prostate. A benign result means that none of these cores contained cancer when examined under the microscope.

A raised PSA level does not always mean that cancer is present in the prostate. Benign prostate tissue is often found in men whose PSA is raised because of an enlarged prostate or inflammation. Our article on understanding your PSA result explains this test in more detail.

How is the diagnosis made?

Benign prostate tissue is diagnosed by a pathologist who examines each biopsy core under the microscope. Normal prostate tissue consists of small glands surrounded by supporting tissue called stroma. The glands produce fluid that mixes with sperm to form semen. Each normal gland is lined by two layers of cells that sit one on top of the other. The inner layer produces the fluid, while the outer layer consists of flat basal cells. Prostate cancer glands lose this outer basal cell layer, a key clue pathologists use. In benign prostate tissue, the glands have normal size, shape, and arrangement, and the lining cells look normal. The basal cell layer surrounds the glands, though it can be hard to see in some areas. The pathologist examines every core before deciding that the result is benign. Many reports describe each core separately, by the part of the prostate it came from.

Immunohistochemistry

Immunohistochemistry uses antibodies to show which proteins cells make. Most benign prostate biopsies do not need any special stains, because the glands look clearly normal. When a group of glands looks unusual, pathologists may use immunohistochemistry to confirm that the glands are benign. Stains you may see on your report include:

p63 and high molecular weight keratin. These stains highlight basal cells, the outer layer of cells around normal prostate glands. High molecular weight keratin may be reported as 34βE12 or CK5. Finding basal cells around the glands supports a benign result.
AMACR. Prostate cancer cells usually make this protein. A negative result supports a benign result, but some harmless glands can be weakly positive.

These stains are often combined into a single test, sometimes called a PIN4 or triple stain. A pathologist interprets the results together with what the glands look like under the microscope.

Other benign findings in a prostate biopsy report

A report showing benign prostate tissue often lists other harmless changes. These changes are common, especially in older men, and none of them are cancer. Some can look like cancer under the microscope, which is why the pathologist may name them in the report. Your report may include:

Atrophy. Some glands have become smaller and their cells thinner. Atrophy is very common and often occurs near areas of inflammation. A related change, called partial atrophy, is one of the most common harmless changes that can look like cancer.
Postatrophic hyperplasia. A cluster of small atrophic glands surrounds a larger central gland. This is a harmless pattern of atrophy that can look crowded under the microscope.
Adenosis. A well-defined group of small, crowded glands, usually in the central part of the prostate. The glands are surrounded by basal cells, although these can be patchy. Some reports use an older name for adenosis, atypical adenomatous hyperplasia.
Basal cell hyperplasia. The basal cells around some glands have increased in number. This is a harmless change that is often seen in an enlarged prostate.
Benign prostatic hyperplasia. An increase in glands and stroma that causes the prostate to enlarge. Our article on benign prostatic hyperplasia explains this condition in more detail.
Chronic inflammation. Collections of immune cells are seen in the prostate tissue. Chronic inflammation is very common and often causes no symptoms. Pathologists sometimes call this change chronic prostatitis.
Acute inflammation. Neutrophils (a type of white blood cell) are seen in or around the glands. Acute inflammation may be seen with an infection of the prostate.
Granulomatous inflammation. Immune cells form small clusters called granulomas. This pattern may follow a previous biopsy or surgery, or treatment of bladder cancer with a medicine called BCG, but it may also occur without a known cause.
Seminal vesicle tissue. The biopsy needle sampled part of the seminal vesicle, a gland that sits just behind the prostate. This tissue is normal, although its cells can have large, irregular nuclei that look unusual under the microscope.

None of these benign findings needs treatment on its own. Your doctor will consider any symptoms, such as signs of an infection, when deciding on the next steps.

Does benign prostate tissue mean I do not have prostate cancer?

A benign prostate biopsy is reassuring because no cancer was found in any of the tissue examined. However, a biopsy samples only a small part of the prostate. A small cancer, or one located in an area the needles did not reach, can be missed. For this reason, a benign biopsy lowers the chance of cancer but does not completely rule it out.

In one large study, some men with a benign first biopsy later had a second biopsy. About 14 in 100 of these men were found to have cancer. A smaller 2023 study looked at 58 men with a benign MRI-guided biopsy who had a repeat biopsy because of continued concern. About 24 in 100 were found to have cancer, but only about 5 in 100 had a cancer of Grade Group 2 or higher. Grade Group 2 or higher is the level usually considered clinically significant. Doctors chose these men for a repeat biopsy because they were still concerned, so the numbers do not apply to every man.

Some reports describe findings that are not cancer but also not fully benign. These include high-grade prostatic intraepithelial neoplasia (HGPIN), a precancerous change in the lining of the glands. Another is atypical small acinar proliferation (ASAP), a small group of glands suspicious for cancer. These findings are explained in separate articles because they may lead to different follow-up.

What happens after the diagnosis?

After benign prostate tissue is found on a biopsy, the next steps depend on your overall risk of prostate cancer. Your care team will consider your PSA level and how fast it is changing, your rectal examination, the size of your prostate, and any MRI results. Your age, general health, and family history of prostate cancer are also considered. In 2026, the American Urological Association and the Society of Urologic Oncology (AUA/SUO) updated their guideline on early prostate cancer detection. It includes these points about follow-up after a benign biopsy:

Continued checkups. A benign biopsy is not a reason to stop prostate cancer screening on its own. Your doctor will usually check your PSA again within the normal screening interval of two to four years, or sooner.
Risk assessment. A PSA level alone should not determine whether another biopsy is needed. Your doctor may use a risk calculator that accounts for the lower risk after a benign biopsy.
Blood, urine, or tissue tests. Men at low risk of significant cancer do not need these extra tests routinely. In other men, doctors may use them selectively to help decide whether another biopsy is needed.
MRI before any repeat biopsy. If a repeat biopsy is planned and no MRI of the prostate has been done, an MRI is recommended first. Any suspicious area seen on the MRI can then be targeted with the biopsy needles.

Benign prostate tissue itself does not need any treatment or further surgery. If your urinary symptoms are caused by an enlarged prostate or inflammation, your doctor can discuss options for managing those conditions.

Questions to ask your doctor

Were all of my biopsy cores benign?
Does my report mention any other findings, such as inflammation or atrophy, and do they matter?
Was HGPIN or ASAP found in any of the cores?
Were special stains used, and what did they show?
What might explain my raised PSA level if no cancer was found?
Did I have an MRI before my biopsy, and were the suspicious areas sampled?
What is my risk of prostate cancer now?
When should my PSA be checked again?
What changes would lead you to recommend another biopsy?